
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Begelomab
Therapeutic Area : Immunology
Study Phase : Phase III
Sponsor : Adienne
Deal Size : Inapplicable
Deal Type : Inapplicable
Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD
Details : Begelomab is a Antibody drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Graft vs Host Disease.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 08, 2015
Lead Product(s) : Begelomab
Therapeutic Area : Immunology
Highest Development Status : Phase III
Sponsor : Adienne
Deal Size : Inapplicable
Deal Type : Inapplicable
